/
KROS
$11.17-$0.04 (-0.36%)prev close
Change$-19.56
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$222.3M
20M shares
52-week range
$9.69 – $22.55
12% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
14.7
Keros Therapeutics, Inc. Common Stock
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
www.kerostx.com- Employees
- 92
- IPO / List date
- Apr 8, 2020
- HQ
- LEXINGTON, MA
Held by traders on TradeandTell
No one on the platform currently holds KROS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 453,482 | $5.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded KROS yet.
